Stem Cell Therapeutics Corp. Announces the Completion of the 90 Day Endpoint Period for the Last Patient Enrolled in the Modifie
April 26 2010 - 6:00AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) is pleased to announce today that the 90- day follow up period
for the last patient enrolled in the modified REGENESIS- Phase IIb
stroke trial has been reached. The modified REGENESIS- Phase IIb
trial, a placebo controlled, double blinded, 3:1 randomized
clinical study, enrolled 96 patients with acute ischemic stroke
between August 2009 and January 24, 2010. This point in the trial
is a major milestone, as it marks the completion of the patient
assessment period and the beginning of the process of compilation,
data analysis and reporting of top-line primary endpoint results
for this key Phase IIb clinical trial of NTx®-265 in acute stroke.
Dr. Alan Moore, President and CEO, commented as follows:
"With the last patient completing their 90-day observation
endpoint, the modified REGENESIS- Phase IIb stroke trial enters
into the exciting stage of data analysis and the reporting of
top-line results. This exhilarating period in the Company's
development is the culmination of solid support from the Company's
shareholders, management and research and development team. SCT
looks forward with great anticipation to the soon to be announced
top-line results of the modified REGENESIS- trial as this truly
marks a key milestone in the development of this new therapy for
stroke patients. With enrollment of the modified Phase IIb stroke
trial ended and data analysis commencing top-line results are
expected within the next 4 weeks, significantly earlier than the
"end of Q2" target that we previously discussed."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO 403-245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager
403-245-5495 ext. 221 adasilva@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Aug 2023 to Aug 2024